ABVC Total Debt To Capitalization from 2010 to 2024
| ABVC Stock | USD 0.51 0.01 1.92% |
Total Debt To Capitalization | First Reported 2010-12-31 | Previous Quarter 0.14900501 | Current Value 0.16 | Quarterly Volatility 3.85967923 |
Check ABVC Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ABVC Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 2.6 M, Selling General Administrative of 5 M or Total Revenue of 157.4 K, as well as many indicators such as Price To Sales Ratio of 31.34, Dividend Yield of 0.0 or PTB Ratio of 0.57. ABVC financial statements analysis is a perfect complement when working with ABVC Biopharma Valuation or Volatility modules.
ABVC | Total Debt To Capitalization |
Latest ABVC Biopharma's Total Debt To Capitalization Growth Pattern
Below is the plot of the Total Debt To Capitalization of ABVC Biopharma over the last few years. It is ABVC Biopharma's Total Debt To Capitalization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ABVC Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Total Debt To Capitalization | 10 Years Trend |
|
Total Debt To Capitalization |
| Timeline |
ABVC Total Debt To Capitalization Regression Statistics
| Arithmetic Mean | (1.05) | |
| Geometric Mean | 0.55 | |
| Coefficient Of Variation | (366.81) | |
| Mean Deviation | 2.26 | |
| Median | 0.19 | |
| Standard Deviation | 3.86 | |
| Sample Variance | 14.90 | |
| Range | 15.3452 | |
| R-Value | 0.47 | |
| Mean Square Error | 12.45 | |
| R-Squared | 0.22 | |
| Significance | 0.07 | |
| Slope | 0.41 | |
| Total Sum of Squares | 208.56 |
ABVC Total Debt To Capitalization History
About ABVC Biopharma Financial Statements
ABVC Biopharma stakeholders use historical fundamental indicators, such as ABVC Biopharma's Total Debt To Capitalization, to determine how well the company is positioned to perform in the future. Although ABVC Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in ABVC Biopharma's assets and liabilities are reflected in the revenues and expenses on ABVC Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ABVC Biopharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Debt To Capitalization | 0.15 | 0.16 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ABVC Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ABVC Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abvc Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abvc Biopharma Stock:Check out the analysis of ABVC Biopharma Correlation against competitors. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share 0.017 | Quarterly Revenue Growth 18.175 | Return On Assets (0.45) | Return On Equity (3.20) |
The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ABVC Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.